7SA9
 
 | | Human MUC16 SEA5 Domain | | Descriptor: | Mucin-16 | | Authors: | Brooks, C.L, White, B. | | Deposit date: | 2021-09-22 | | Release date: | 2022-03-23 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.69 Å) | | Cite: | Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker.
Proteins, 90, 2022
|
|
7U8C
 | | Crystal structure of Mesothelin C-terminal peptide-MORAb 15B6 FAB complex | | Descriptor: | MORab 15B6 Fab heavy chain, MORab 15B6 Fab light chain, Mesothelin, ... | | Authors: | Zhan, J, Esser, L, Xia, D. | | Deposit date: | 2022-03-08 | | Release date: | 2022-06-08 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.74 Å) | | Cite: | Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
7U9J
 | | Crystal structure of Mesothelin-207 fragment | | Descriptor: | GLYCEROL, Isoform 3 of Mesothelin, SULFATE ION | | Authors: | Zhan, J, Esser, L, Lin, D, Tang, W.K, Xia, D. | | Deposit date: | 2022-03-10 | | Release date: | 2023-02-01 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (2.09 Å) | | Cite: | Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.
Cancer Res Commun, 3, 2023
|
|
8VRS
 | | Mucin 16 peptide fused to MBP in complex with 4H11-scFv antibody | | Descriptor: | 4H11 scFv chain, Maltose/maltodextrin-binding periplasmic protein,Mucin-16 | | Authors: | Lee, K, Perry, K, Yeku, O.O, Spriggs, D.R. | | Deposit date: | 2024-01-22 | | Release date: | 2024-04-03 | | Method: | X-RAY DIFFRACTION (2.47 Å) | | Cite: | Structural basis for antibody recognition of the proximal MUC16 ectodomain.
J Ovarian Res, 17, 2024
|
|
8CZ8
 | | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | | Descriptor: | Mesothelin, cleaved form, SULFATE ION, ... | | Authors: | Bandaranayake, A.D, Rupert, P.B, Lin, I, Pilat, K, Ruff, R.O, Friend, D.J, Chan, M.K, Clarke, M, Carter, J, Meshinchi, S, Mehlin, C, Olson, J.M, Strong, R.K, Correnti, C.E. | | Deposit date: | 2022-05-24 | | Release date: | 2023-06-07 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics
Front. Drug Discov., 3, 2023
|
|
8GKL
 | | Crystal Structure of the Humanized MUC16 Specific Antibody huAR9.6 | | Descriptor: | MUC16 antibody AR9.6 Fab heavy chain, MUC16 antibody AR9.6 Fab light chain, Mucin-16 | | Authors: | Brooks, C.L, Aguilar, E.N. | | Deposit date: | 2023-03-19 | | Release date: | 2024-03-20 | | Last modified: | 2024-10-02 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.
Mol.Cancer Ther., 23, 2024
|
|
4F3F
 | | Crystal Structure of Msln7-64 MORAb-009 FAB complex | | Descriptor: | MORAb-009 Fab heavy chain, MORAb-009 Fab light chain, Mesothelin | | Authors: | Xia, D, Pastan, I, Ma, J, Tang, W.K, Esser, L. | | Deposit date: | 2012-05-09 | | Release date: | 2012-07-11 | | Last modified: | 2023-09-13 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.
J.Biol.Chem., 287, 2012
|
|
8VM1
 | |
8FSL
 | |
7UED
 | | Crystal structure of full length mesothelin bound with MORAb-009 Fab | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, Isoform 4 of Mesothelin, ... | | Authors: | Zhan, J, Esser, L, Lin, D, Tang, W.K, Xia, D. | | Deposit date: | 2022-03-21 | | Release date: | 2023-02-01 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.
Cancer Res Commun, 3, 2023
|
|
8CYH
 | | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, A12 antibody heavy chain, A12 antibody light chain, ... | | Authors: | Bandaranayake, A.D, Rupert, P.B, Lin, I, Pilat, K, Ruff, R.O, Friend, D.J, Chan, M.K, Clarke, M, Carter, J, Meshinchi, S, Mehlin, C, Olson, J.M, Strong, R.K, Correnti, C.E. | | Deposit date: | 2022-05-23 | | Release date: | 2023-06-07 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (3.38 Å) | | Cite: | Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics
Front. Drug Discov., 3, 2023
|
|
8CX3
 | | Crystal structure of full-length mesothelin | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, ... | | Authors: | Zhan, J, Esser, L, Xia, D. | | Deposit date: | 2022-05-19 | | Release date: | 2023-02-01 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (3.609 Å) | | Cite: | Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.
Cancer Res Commun, 3, 2023
|
|
8CXC
 | | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | | Descriptor: | 3F2 Antibody heavy chain, 3F2 Antibody light chain, Mesothelin, ... | | Authors: | Bandaranayake, A.D, Rupert, P.B, Lin, I, Pilat, K, Ruff, R.O, Friend, D.J, Chan, M.K, Clarke, M, Carter, J, Meshinchi, S, Mehlin, C, Olson, J.M, Strong, R.K, Correnti, C.E. | | Deposit date: | 2022-05-20 | | Release date: | 2023-06-07 | | Last modified: | 2024-05-01 | | Method: | X-RAY DIFFRACTION (4.31 Å) | | Cite: | Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics
Front. Drug Discov., 3, 2023
|
|
